Although carbon ion therapy facilities are expensive, the biological effects of carbon ion beam treatment may be better against cancer (and cancer 
Introduction
Colorectal cancer is currently the most common gastrointestinal malignancy and remains the third most common cancer and second leading cause of cancer-related deaths in developed countries (1) . Although surgical resection has been the first choice for treatment of colorectal cancer, half of patients still suffer recurrence, presumably because of disseminated micrometastases present at the time of surgery (2) . Radiation therapy is the most effective nonsurgical intervention for cancer treatment, but most cancers also invariably recur after radiation therapy. Therefore, determination of the mechanisms of recurrence and radioresistance in these tumors and development of powerful therapeutics could lead to advances in the treatment of cancer.
The Heavy-Ion Medical Accelerator in Chiba (HIMAC) is the first heavy-ion accelerator specially dedicated to medicine in the world and has now become the world's leading heavy-ion cancer treatment facility (3, 4) . Although heavy-ion beam facilities are large scale and hugely expensive, several new heavy-ion therapy facilities, such as CNAO (Italy), PTC Marburg (Germany), SAGA HIMAT (Japan), ETOILE (France), Shanghai Particle Therapy Hospital (China), and Mayo Clinic (USA), are under construction or in planning worldwide. A one-third smaller and cheaper carbon ion radiotherapy facility based on the highly advanced technology was designed and constructed in Gunma University in Japan, and clinical trial was successfully initiated in March 2010. High linear energy transfer (LET) particle therapy has various advantages because of the production of spread out Bragg's peaks (SOBP), which cover tumors with biologically equivalent dose distributions. Therefore, high LET heavy-ion therapy has several potential advantages over low LET photon therapy such as increased relative biological effect, reduced oxygen enhancement ratio, decreased cellcycle-dependent radiosensitivity, and induced complex DNA damage that is not easily repaired (5, 6) . Over the past decades, HIMAC has been successful in treating more than 5,000 cases of various human cancers and achieved promising clinical outcomes for many radioresistant tumor types, including recurrent colorectal cancer, hepatocellular carcinoma, chondroma, and sarcoma (7) (8) (9) (10) .
Recently, cancer stem cells have been identified in a growing number of solid tumors, which are typically recognized by virtue of the expression of cell surface markers; most of them are transmembrane glycoproteins, such as CD133, CD44, and EpCAM (ESA; refs. 11, 12) . Cancer stem cells have the ability to generate tumors that recapitulate the original tumor when xenotransplanted into animals, whereas the remaining noncancer stem cell tumor bulk most often cannot (13) (14) (15) (16) (17) (18) . The cancer stem cells that populated the original tumor may have resistance to the treatments to repopulate the recurrent tumor even after the bulk of the tumor has been removed by resection or chemoradiation therapy (19) (20) (21) (22) . Therefore, the key point in curatively treating cancer is how to effectively eradicate those minor cancer stem cells in the bulk of the tumor (23) (24) (25) . Because heavy-ion radiotherapy has potential advantages in treating many human radioresistant cancers, we hypothesize that heavy-ion irradiation may effectively target these cancer stem-like cells. To the best of our knowledge, our study is the first to explore whether heavy-ion irradiation may have advantages over X-rays in targeting human colon cancer stem-like cells.
Materials and Methods

Cell lines
The colon adenocarcinoma cell lines HCT116 and SW480 were purchased from American Type Culture Collection. The cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Invitrogen) supplemented with 10% with heat-inactivated 5% (v/v) fetal calf serum (FCS; Beit-Ha'Emek), 100 unit/mL penicillin, and 100 mg/mL streptomycin (Invitrogen) in a 37 C with 5% CO 2 in air. The medium was changed every other day.
Colony and spheroid formation assay
A clonogenic survival assay was conducted as described previously (6) . In brief, the appropriate plating density was designed to produce 20 to 40 surviving colonies in each 6-cm dish or T25 flask. After incubation for 14 days, the colonies were fixed and stained with 0.3% methylene blue in ethanol, and colonies containing more than 50 cells were counted as survivors. At least, 3 parallel samples were scored in 3 to 5 repetitions conducted for each irradiation condition.
For assays of clonogenicity and ability to grow as "tumor spheres" in suspension, HCT116 and SW480 cells were sorted to obtain populations of CD133 subpopulations were then resuspended in a cell density of 500 or 2,000 cells/mL and were plated triplicate in a 6-cm dish or 96-well plates precoated with a layer of 1% agarose and left to grow for 1 to 2 weeks. To quantify the number of colonies and sphere formations as well as spheroid formation rates, each positive or negative stem-like cell was applied to 12 wells, the rate of spheres per well calculated, and the data are presented as percentage of the wells that contained spheres.
In vivo tumorigenic assays
Immediately after sorting, aliquots of the particular cell populations were counted and cell viability was determined using a conventional trypan blue test. The sorted cells were centrifuged at 300 Â g for 5 minutes at 4 C, suspended in serum-free medium (DMEM with 1% penicillin/streptomycin), then various numbers of CD133
and CD44 À /ESA À cells ranging from 1 Â 10 3 to 2 Â 10 5 cells are injected subcutaneously into the hind legs of 6-to 8-weekold male NOD/SCID (severe combined immunodeficient mice)mice. The animals were sacrificed at the indicated time intervals (4-10 weeks) when tumor nodules were identified on their body surfaces. Tissues were fixed in formaldehyde and examined histologically. All experiments involving the use of animals were carried out in accordance with NIRS institutional animal welfare guidelines. NOD/SCID mice (Charles River Laboratories) were maintained under defined conditions at the NIRS Animal Facility.
Tumor growth delay assays
BALB/cAJcl-nu/nu male mice (5-week-old) were purchased from CLEA Japan, Inc. Mice were provided with water and food ad libitum and were housed at 5 animals per cage. All surgical procedures and care administered to the animals were in accordance with the NIRS Animal Care and Use Committee. Tumors were established by subcutaneous inoculation of 8 Â 10 5 HCT116 cells into the right leg of the mouse. Tumor growth was monitored every 3 days by measuring 2 perpendicular diameters. Tumor volume was calculated according to the formula: 0.52 Â a Â b 2 , where a and b are the largest and smallest diameters, respectively. The tumor growth delay (TGD) of xenograft tumors after treatment with X-rays or carbon-ion was estimated at the tumor volume of 500 mm 3 . The relative biological effectiveness (RBE) of carbonions at the middle of a 6-cm SOBP relative to 200 keV X-rays was calculated by KaleidaGraph software.
Irradiation
Cells or mice were irradiated with carbon-ion beams accelerated by the HIMAC at NIRS. The details concerning the beam characteristics of the carbon-ion beams, biological irradiation procedures, and dosimetry have been described elsewhere (3, 4) . Briefly, the initial energy of the carbon-ion beams was 290 MeV/n, 50KeV/mm, 6-cm, SOBP. The energy of heavy-ion beams at the irradiation site was obtained by comparing the calculated and measured depth-dose distribution. As a reference, mice were also irradiated with conventional 200 kV p X-rays (Pantac HF-320S; Shimadzu Co.) at NIRS. Cells were irradiated with 2, 4, 6, or 8 Gy of X-rays or 1, 2, 4, or 6 Gy carbon ions. Transplanted xenograft tumors were irradiated with various doses of X-rays (15, 30 , and 60 Gy) or carbon-ions (5, 15, and 30 Gy).
FACS analysis
FACS (fluorescence-activated cell sorting) analysis for the cells or xenograft tumors irradiated with X-rays or carbon ion was conducted with BD FACSAria according to the manufacturer's protocol (Becton Dickinson 
Gross morphology and histopathology
Gross morphologic changes were followed up to 12 weeks after a single fraction of X-ray or carbon-ion radiation. At selected time points, tumors were excised and histopathologic examinations were conducted. Xenograft tumors from different groups were fixed in 10% neutral formalin and processed in paraffin-embedded sections followed by sectioning (4 mm) onto slides. Sections were stained with hematoxylin and eosin (H&E) and assessed microscopically.
Immunohistochemistry
Immunohistochemical staining was conducted with the Elite ABC Kit (Vector Laboratories) according to the manufacturer's protocol (26, 27) . In brief, sections cut from formalin-fixed, paraffin-embedded tissue blocks were deparaffinized and rehydrated through a graded series of ethanol and incubated in 0.3% hydrogen peroxidase in methanol to block endogenous peroxidase action. For antigen retrieval, sections were placed in boiling 10 mmol/L citrate buffer (pH 6.0). The slides were preincubated with normal horse serum (1:50 dilution; Vector Laboratories) to diminish nonspecific binding of the secondary antibody and then incubated overnight at 4 C with anti-CD133 (AC133, human monoclonal; Miltenyi Biotec; 1:200 dilution), anti-CD44 (mouse monoclonal; BD Transduction Labs; 1:100 dilution), and anti-ESA (human monoclonal; Miltenyi Biotec; 1:200 dilution). Slides were then rinsed and incubated with universal secondary antibody containing antimouse/anti-goat IgG (Vectastain ABC Elite kit; Vector Laboratories) for 30 minutes, developed with diaminobenzadine (Vectastain ABC Elite kit; Vector Laboratories) for 10 minutes, and counterstained with hematoxylin for 2 minutes. Ten fields were selected and expression was evaluated in 1,000 tumor cells with high power (200Â) microscopy. As a negative control, the sections were stained without primary antibodies to monitor the background staining level. Cytoplasmic and/or membrane staining were considered to indicate specific CD133, CD44, and ESA immunoreactivity. Each slide was assessed for the intensity of immunostaining, background, and percentage of cells expressing the target protein.
Western blotting
Western blot analyses were conducted as previously described (26) . Cells or tumor tissues were lysed using the Pierce Nuclear and Cytoplasmic Extraction Reagent Kit (Pierce). Samples were normalized for protein concentration using the Pierce BCA protein assay; 50 mg of each cytoplasmic or nuclear extract sample was analyzed by SDS/5% PAGE and transferred to a polyvinylidene difluoride (PVDF) membrane. Membranes were blocked with 2% ECL Advance Blocking Agent in TBS Tween 20 for 1 hour and probed overnight with monoclonal antibodies specific for CD133, ESA, and CD44. b-Actin was used as a loading control. Subsequently, membranes were incubated with rabbit anti-mouse or anti-rabbit horseradish peroxidase-conjugated secondary antibody (Sigma-Aldrich). Blots were visualized by ECL Advanced Kit (GE Healthcare Life Sciences) and quantitated using ImageQuant LAS 4000 Mini Biomolecular Imager. Densitometric analysis was obtained with Fujifilm Multi Gauge Software (version 3.0).
Statistical analysis
One-way ANOVA and Bonferroni multiple comparison tests were used when mean differences between the groups were evaluated by StatView software (SAS Institute, Inc.). For all comparisons, values of P < 0.05 were defined as significant.
Results
Survival fraction by carbon-ion versus X-ray irradiation
The HCT116 and SW480 cells were irradiated with carbonion or X-rays up to 6 Gy, and their survival fraction was measured from the colony formation. Figure 1 shows doseresponse curves for cell killing effects on the 2 human colon cancer cell lines irradiated with X-rays or 50 keV/mm SOBP carbon ion beams. The surviving fractions for the HCT116 and SW480 irradiated with X-rays and carbon ions decreased exponentially with increasing doses. On the basis of these survival curves, the RBE values calculated by the D10, which is determined as the dose (Gy) required to reduce the surviving fraction to 10%, relative to X-rays, is about 1.63 to 1.74 for carbon-ion beams.
Determination of cancer stem-like cell properties of 
CD44
À /ESA À (P < 0.01; Fig. 2B ). Figure 2C shows representative positive cells for CD133, CD44, and ESA markers.
To determine the efficacy of tumor initiation from cells with or without CD133, CD44, and ESA markers, we carried out limiting dilution experiments. A variable number of human cells, ranging from 1,000 to 2,000,000, were injected into NOD/ SCID mice to test their xenotumor abilities. As few as 1000 
Changes in proportion of cancer stem-like cells in vitro by carbon-ion versus X-ray irradiation
In vitro FACS analyses showed that the percentage of cancer stem-like cells which were positive for CD133, CD44, and ESA were more significantly increased after 48 or 72 hours X-ray than carbon ion irradiation. The percentage of CD133 þ cells in unirradiated HCT116 cells was about 3%, and it was increased more than 3-fold after irradiation with 2 Gy X-rays and further increased 5-fold after 4 Gy X-ray irradiation. In comparison, CD133 þ cells were increased only 2-fold by 1 Gy carbon ion and 3-fold by 2 Gy carbon ion irradiation for which the doses induced equivalent effects by X-ray. The percentage of CD44 þ cells was increased by more than 1.5-fold after irradiation with 2 Gy X-rays and further increased 2.5-fold after 4 Gy X-ray irradiation. In contrast, CD44 þ cells were unchanged by 1Gy carbon ion and decreased 0.5-fold by 2 Gy carbon ion irradiation. Interestingly, the percentage of ESA þ cells did not change by either 2 or 4 Gy but increased 2-fold by 6 Gy X-rays irradiation. In contrast, ESA þ cells were unchanged after carbon ion irradiation even by the dose up to 4 Gy (Fig. 3A) . The proportion of CD133
þ cells were enriched 2-to 3-fold by 2 or 4 Gy X-rays, whereas those of double positive cells were decreased or unchanged by 1 or 2 Gy carbon ion irradiation (Fig. 3A) .
Clonogenic assays of cancer stem-like cells in vitro by carbon-ion versus X-ray irradiation
Clonogenic assays were conducted to determine the different radiosensitivity of cancer stem-like cells between carbon ion and X-ray irradiation. Figure 3B shows 
TGD and relative biological effects of carbon-ion relative to X-ray irradiation
Transplanted xenograft tumors grow fast without any treatment and the tumor volume became more than 400 mm 3 after being subcutaneously implanted into mice for 3 weeks. Treatment with X-rays (30 Gy) effectively suppressed tumor growth and reduced the tumor size and volume about 10%, but the tumor rapidly regrew after 4 weeks and to double in volume after another 4 weeks (Fig. 4A) . In contrast, treatment with carbon-ion (30 Gy) radiation increased tumor size at the first week and then gradually decreased. The tumor was reduced to the same size as prior to radiation after 4 weeks and actually became less than half in volume after 8 weeks, and finally disappeared after 12 weeks without any regrowth and relapse (Fig. 4A) . To determine the tumor growth control possibility by carbon-ion radiation, the xenograft tumors were also treated with various doses. Carbonion irradiation with 15 Gy can suppress tumor growth without significant initial increase in tumor size and volume but regrew after 7 to 8 weeks. As expected, treatment with 5 Gy carbon-ion or 15 Gy X-ray failed to control tumor growth anymore; however, the tumor was completely regressed without regrowth with 60 Gy X-ray irradiation in the 12-week follow-up (data not shown). Xenotransplanted tumor control possibility by carbon-ion and X-ray radiation at various doses is summarized in Table 2 . To calculate in vivo RBE values, the TGD of xenotransplanted tumors after treatment with 15 or 30 Gy of X-rays and 5 or 15 Gy carbon-ions were estimated. Due to the tumor bed effect, the extent of TGD determined from tumor growth curves is highly dependent on the end volume chosen. To minimize the influence of the tumor bed effect on the growth delay, we calculated by choosing a smaller size and essentially an earlier time for regrowth. The TGD was obtained according to the endpoint of the tumor regrown to a volume of about 500 mm 3 . As shown in Table 3 , TGD was 4 and 28 days for 15 and (Fig. 4B) . On the basis of this TGD, the RBE values of 50 keV/mm carbon ion at the middle of a 6-cm SOBP relative to X-ray were calculated as 3.05 to 3.25 according to the formula analyzed by KaleidaGraph software (Fig. 4B and Table 3 ). Figure 4C illustrates gross tumor morphology before and after treatment with carbon-ion (15, 30 Gy) or X-ray (30 Gy) irradiation. Tumor-supplying vessels were very clearly seen in the unirradiated mice as well as in the X-ray irradiated mice, but markedly reduced in carbon-ion irradiated mice. It is further confirmed by microscopy observation that the microvessel counts were significantly reduced by carbon ion compared with X-ray irradiation (Fig. 4D) . Histopathologic changes of xenograft tumors after irradiation with X-rays or carbon-ion for 4 weeks were examined by H&E staining. Histopathologic features showed that most of the tumor cells were not disrupted by 15 Gy X-rays or 5 Gy carbon ion irradiation (data not shown). At the same level of biological efficacy, 15 Gy carbon-ion irradiation predominantly induced colon cancer cell cavitations, fibrosis and the duct-like architecture was completely disrupted. In contrast, 30 Gy X-ray irradiation only partially destroyed colon cancer cells and the duct-like architecture still remained (Fig. 4D) . It is clearly shown that almost all of the tumor cells were destroyed after irradiated with 30 Gy carbon-ions (Fig. 4D) .
Gross morphologic and histopathologic changes after carbon-ion versus X-ray irradiation
Expression of cancer stem-like cell marker CD133, CD44 and ESA after carbon-ion versus X-ray irradiation
The expression changes of cancer stem cell marker CD133, CD44, and ESA in the xenograft tumors at 4 weeks after irradiation with 30 Gy X-rays or carbon-ion (15, 30 Gy) were examined by immunohistochemical staining. It was shown that expression of both CD133 and CD44 was significantly suppressed by 15 Gy carbon-ion irradiation compared with unirradiated tumors, except ESA protein, but all 3 putative cancer stem cell proteins were remarkably inhibited after treatment with 30 Gy carbon-ion irradiation. In contrast, 30 Gy X-rays significantly increased expression of CD133, CD44, and ESA compared with those of unirradiated tumors (Fig. 5A) . It was further confirmed by Western blotting analyses that expression levels of all CD133, CD44, and ESA proteins was significantly enhanced by 30 Gy X-rays compared with 15 Gy carbon-ion irradiation and all 3 proteins were predominantly reduced by 30 Gy carbon-ion irradiation (Fig. 5B) .
Changes in proportion of cancer stem-like cells in vivo by carbon-ion versus X-ray irradiation
In vivo FACS analyses showed that the percentage of cancer stem-like cells which were positive for CD133, ESA were increased with 15 and/or 30 Gy but significantly decreased with 60 Gy X-rays irradiation after 1 month. In comparison, carbon-ion irradiation with 15 Gy did not change the percentage of these positive cancer stem-like cells, whereas irradiation with 30 Gy significantly reduced the percentage of positive cancer stem-like cells (Fig. 5C ). It is not detectable in any of cancer stem-like cells by in vivo FACS analysis after the tumor irradiated with 30 Gy carbon ion or 60 Gy X-rays for 2 to 3 months.
Discussion
We found that the in vitro RBE values, calculated by the D10 relative to the X-rays, are about 1.63 to 1.74 for the 50-keV/mm SOBP carbon ion beam on HCT116 or SW480 cells in this study. RBE values are known to be dependent on LET, and our results are almost consistent with previous reports using HIMAC carbon-ion beams on various human cancer cell lines such as lung, pancreas, and brain tumors, which reported 1.06 to 1.33 for a 13-keV/mm-beam, 1.42 to 1.69 for a 50-keV/mmbeam, and 2.00 to 3.01 for a 77-keV/mm-beam (4, 28) . Recent accumulating experimental evidence suggests that cancer stem cell content may differ among tumors and that a higher proportion of cancer stem cells is correlated with higher In the present study, FACS analyses showed that the proportion of cancer stem-like cells which were positive for CD133, ESA, and CD44 was more highly enriched after X-ray compared with carbon ion irradiation, particularly, the population of CD133 þ , CD44 þ cells was increased more than 2-fold (2-4 Gy) by X-ray irradiation. In contrast, CD133 þ and CD44 þ cells were unchanged or decreased by carbon-ion irradiation (1-2 Gy). Interestingly, the proportion of ESA þ cells was increased by 6 Gy X-ray irradiation but without changes by carbon-ion irradiation even the dose was up to 4 Gy. The proportion changes of double positive CD133
þ cells by X-ray versus carbon-ion irradiation were showed same responses. These finding suggests that low LET X-ray irradiation may mainly kill the nonstem-like tumor cells, as a result the radioresistant cancer stem-like cell population was predominantly enriched. In contrast, carbon-ion irradiation may concurrently kill both non-stem-like and stem-like tumor cells; consequently, the population of cancer stem-like cells was only slightly increased or unchanged. To directly determine the radiosensitivity of cancer stem-like cells between carbon ion and X-ray irradiation, a colony assay was conducted. On the basis of the dose-response curves for cell killing effect on cancer stem-like cells and noncancer stem-like cells after irradiation with either X-rays or carbon ion beams, the cancer stem-like cells showed resistance to both X-rays and carbon ions. The surviving fractions for the cancer stem-like cells after irradiation with X-rays or carbon ions decreased exponentially with increasing doses. The RBE values calculated at the D10 level for cancer stem-like cells were about 2.05 to 2.28, suggesting that carbon ion beam has a promising potential to destroy cancer stem-like cells. In contrast, RBE values at the D10 level for noncancer stem-like cells were only 1.22 to 1.44, implying that there are no significant differences in the killing of noncancer stem-like cells between the carbon ion beam and X-ray irradiation. Altogether, these results can also partially explain why the proportion of cancer stem-like cells after irradiation with X-rays is more enriched than those of carbon-ion beams.
In vivo study showed that 15 or 30 Gy carbon-ion irradiation predominantly induced colon cancer cell cavitations, fibrosis, and completely disrupted the duct-like structure, whereas 30 Gy X-ray irradiation only partially disrupted colon cancer cells and the duct-like structure still remained when the xenograft tumors were histopathologically examined after 4 weeks. The tumor-supplying vessels were exactly reduced in carbon-ion irradiated mice compared with those of X-rays irradiated mice. This finding is in agreement with a previous report that heavy-ion irradiation inhibits in vitro angiogenesis (29) . Several previous studies reported that the in vivo RBE values for high LET carbon-ion beams ranged from 2.0 to 3.1 (30, 31) . In the present study, the in vivo RBE was calculated as 3.05 to 3.25 from the slope of the dose-response curve for tumor growth suppression by carbon ions relative to X-rays, which is almost in line with previous reports (30, 31) . It is known that RBE is a complex quantity, depending on many factors such as particle type, dose per fraction, and LET, as well as on biological factors like cell or tissue type and the selected biological endpoint. The extent of TGD determined from tumor growth curves is highly dependent on the end volume chosen because of tumor bed effects (32) . This may be the reason why the RBE values calculated in this study are a little higher than other reports. In addition, because a low number of dose levels were applied in this study, further studies are needed on in vivo RBE of carbon ions for local tumor control.
Recently, accumulating evidence showed that expression of cancer stem-like cell markers such as CD133, CD44 were closely related with patient's clinical outcome and prognosis as well as chemoresistance (33) (34) (35) (36) . In the present study, we surprisingly found that 15 Gy carbon-ion irradiation induced more severe tumor cell disruption without significant increment of putative cancer stem cell markers CD133, CD44, and ESA, whereas X-rays irradiation remarkably increased these protein levels. All these cancer stemlike cell markers were remarkably inhibited after treatment with 30 Gy carbon-ion irradiation. Furthermore, in vivo FACS analyses showed that the proportion of cancer stem-like cells which were positive for CD133, ESA were enriched by 15 and/or 30 Gy but significantly decreased by 60 Gy X-ray irradiation after 4 weeks. In comparison, carbon-ion irradiation with 15 Gy did not change the percentage of these positive cancer stem-like cells, whereas irradiation with 30 Gy significantly reduced the percentage of positive cancer stem-like cells. However, none of cancer stem-like cells were detectable by FACS analysis after the tumors were irradiated with 30 Gy carbon ions or 60 Gy X-rays for 2 to 3 months. Presumably, the doses to completely destroy the cancer stem cells are dependent on the tumor cell type as well as cancer stem cell population in the tumor bulk.
Altogether, according to the cancer stem cell model, therapeutic approaches that are not capable of eradicating the cancer stem cell subset are unlikely to be successful because they might be able to kill the majority of tumor cells and induce regression of tumor lesions but fail to prevent disease relapse and metastatic dissemination (23-25, 37, 38) . Based on this understanding, although carbon ion beam facilities are very expensive, to achieve better outcomes as well as a better quality of life for patients with some types of cancer, such as unresectable sacral chondromas (39) or locally recurrent rectal cancer (40) , carbon-ion beam therapy may be worth the cost. In conclusion, our findings presented here are the first to show that carbon ion beam therapy may have advantages over photon beam therapy in targeting putative colon cancer stem-like cells.
